Human Anti-SIRPA Recombinant Antibody (clone 29-AM3-4); Fab Fragment (CAT#: HPAB-0024-LSX-F(E))

1. Q 1: What is the primary application of the Anti-SIRPA Fab Fragment in research?

   A: The Anti-SIRPA Fab Fragment (clone 29-AM3-4) is primarily used in ELISA to study the interaction between CD47 and SIRPα, which is a key focus in cancer immunotherapy research. This fragment format allows researchers to investigate the underlying mechanisms of immune evasion by tumors, facilitating the development of potential therapeutic strategies.

2. Q 2: How does the Fab Fragment format benefit studies involving SIRPA?

   A: The Fab Fragment format enhances tissue penetration due to its smaller size compared to full-length antibodies, making it highly suitable for in vivo studies and imaging applications. Its ability to precisely target and block specific sites on SIRPα enables detailed examination of immune checkpoint roles in diseases, thereby aiding in therapeutic research and development.

3. Q 3: How does the Anti-SIRPA Fab Fragment contribute to the study of acute myeloid leukemia (AML)?

   A: The Anti-SIRPA Fab Fragment is pivotal in research on AML due to its ability to block the CD47-SIRPα pathway, often utilized by cancer cells to evade immune clearance. By interrupting this pathway, the Fab fragment facilitates the exploration of potential therapies that activate macrophage-mediated phagocytosis of leukemia cells, providing insights into novel treatment options for AML.

View the frequently asked questions answered by Creative Biolabs Support.